Similar articles for PMID: 31959660

Year	Number of Results
2003	3
2004	1
2008	2
2009	1
2010	1
2012	1
2013	4
2014	5
2015	15
2016	7
2017	8
2018	17
2019	11
2020	5
2021	1
2022	1
2024	0

1

Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market.

Randhawa PA, Brar R, Nolan S. Randhawa PA, et al. CMAJ. 2020 Jan 20;192(3):E73. doi: 10.1503/cmaj.74018. CMAJ. 2020. PMID: 31959660 Free PMC article. No abstract available.

2

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.

Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, Mathias S, Azar P. Rozylo J, et al. Addict Sci Clin Pract. 2020 Jan 15;15(1):2. doi: 10.1186/s13722-020-0177-x. Addict Sci Clin Pract. 2020. PMID: 31941547 Free PMC article.

3

The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients.

Baykara S, Alban K. Baykara S, et al. Psychiatry Res. 2019 Feb;272:450-453. doi: 10.1016/j.psychres.2018.12.153. Epub 2018 Dec 29. Psychiatry Res. 2019. PMID: 30611963

4

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.

Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. Tanum L, et al. JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205. doi: 10.1001/jamapsychiatry.2017.3206. JAMA Psychiatry. 2017. PMID: 29049469 Free PMC article. Clinical Trial.

5

The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.

Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D. Socias ME, et al. Contemp Clin Trials. 2018 Jun;69:21-27. doi: 10.1016/j.cct.2018.04.001. Epub 2018 Apr 5. Contemp Clin Trials. 2018. PMID: 29627621 Free PMC article. Clinical Trial.

6

Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.

Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Klaire S, et al. Am J Addict. 2019 Jul;28(4):262-265. doi: 10.1111/ajad.12869. Epub 2019 Mar 22. Am J Addict. 2019. PMID: 30901127

7

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Mendelson J, Jones RT. Mendelson J, et al. Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. doi: 10.1016/s0376-8716(03)00057-7. Drug Alcohol Depend. 2003. PMID: 12738348 Review.

8

Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.

Soper R, Appajosyula S, Deximo C. Soper R, et al. Adv Ther. 2018 Apr;35(4):457-466. doi: 10.1007/s12325-018-0696-y. Epub 2018 Apr 6. Adv Ther. 2018. PMID: 29623562

9

Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.

Gunderson EW, Hjelmström P, Sumner M; 006 Study Investigators. Gunderson EW, et al. Clin Ther. 2015 Oct 1;37(10):2244-55. doi: 10.1016/j.clinthera.2015.08.025. Epub 2015 Sep 26. Clin Ther. 2015. PMID: 26412801 Free article. Clinical Trial.

10

Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Rosenblatt RA, et al. Ann Fam Med. 2015 Jan-Feb;13(1):23-6. doi: 10.1370/afm.1735. Ann Fam Med. 2015. PMID: 25583888 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

75 results

Results by year